… All these agents are associated with a range of adverse events (AEs) that can have a …
adverse events in phase 3 trials of tyrosine kinase inhibitors in advanced hepatocellular carcinoma…

… Sorafenib is the standard treatment for patients with hepatocellular carcinoma (HCC) with …
assessing the prognostic significance of sorafenib-related adverse events is provided. …

… of the patients with surgically unresectable hepatocellular carcinoma (HCC). Sorafenib …
In this review, we discussed the mechanism of sorafenib-associated adverse events and …

… for hepatocellular carcinoma for over a decade. Its tolerability is limited by different adverse
events… physicians’ experience in managing adverse events related to sorafenib has improved …

… The most common adverse events (AEs) in pts treated with LEN were hypertension and
diarrhea. In addition, LEN showed a different AE profile from that of SOR. Pts who received LEN …

Background and Aim Lenvatinib is a standard of care option in first‐line therapy of advanced
hepatocellular carcinoma (HCC). In the present study, we aim to identify, in patients with …

… Introduction: Development of immune-related adverse events (irAEs) has been associated
… such an association exists in advanced hepatocellular carcinoma (aHCC). This study aims to …

… with the discontinuation of lenvatinib (LEN) due to severe adverse events (DLSAE) in patients
with unresectable hepatocellular carcinoma (HCC). This retrospective study enrolled 177 …

… adverse events have been pointed out. This review summarizes the antitumor effects and
adverse events … For the meta-analysis of adverse events, we used the RCTs for solid cancers. …

… and ICI efficacy in hepatocellular carcinoma (HCC) patients. … The most frequent adverse
event was diarrhea/colitis (n = 6), and the … There was no grade 3 adverse event observed in our …